The Wellness · Health News
Clinical
Trial results, drug approvals, biotech
19 Aug 2026NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures show the bowel cancer screening programme is identifying roughly 100 cancers every week, even as participation among people in their 50s remains below desired levels.
19 Aug 2026EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators moved to expedite their assessment of a Revolution Medicines oncology drug, one of several notable regulatory developments reported by STAT News on July 8, 2026.
- 19 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have agreed to expedite their assessment of a Revolution Medicines oncology candidate, according to a July 2026 STAT News report covering several notable regulatory developments.
- 18 Aug 2026
Bowel Screening Uptake Lags in 50s as 100 Cancers Found Weekly
Annual NHS England screening figures reveal that people in their 50s are among the least likely age groups to return bowel cancer testing kits, even as the programme identifies roughly 100 cancers every week.
- 18 Aug 2026
Three Biotech Developments Shaping Drug Review Pipelines
A cluster of regulatory decisions is drawing attention across oncology, autoimmune disease, and metabolic medicine, with outcomes ranging from expedited review to emerging safety questions.
- 18 Aug 2026
Bowel Screening Finds 100 Cancers Weekly in Over-50s
New NHS England figures reveal that bowel cancer screening is identifying roughly 100 cases per week among people in their 50s, even as participation rates in this age group trail behind older cohorts.
- 18 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
A cluster of regulatory decisions in July 2026 reshaped the near-term outlook for three biotechs, spanning oncology, autoimmune disease, and oral weight-loss medicine.
- 17 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators moved to expedite their assessment of a Revolution Medicines drug, according to a July 2026 STAT News report covering several notable regulatory developments.
- 17 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week in People in Their 50s
New NHS England figures show bowel cancer screening is detecting roughly 100 cancers per week among people in their 50s, even as participation rates in that age group trail behind older cohorts.
- 17 Aug 2026
Three Biotech Regulatory Shifts Reshaping Drug Pipelines
A cluster of regulatory developments is altering the near-term outlook for several drug candidates, spanning oncology, autoimmune disease, and metabolic medicine.
- 16 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures covering April 2024 to March 2025 reveal that participation in bowel cancer screening remains notably low among people in their 50s, even as the programme identifies around 100 cancers every week.
- 16 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have agreed to accelerate their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report that also covers an FDA clearance and emerging concerns around an oral GLP-1 candidate.
- 16 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures covering April 2024 to March 2025 show the bowel cancer screening programme is detecting around 100 cancers per week, even as participation among people in their 50s remains comparatively low.
- 16 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have agreed to expedite their assessment of Revolution Medicines' cancer drug, according to a July 2026 STAT News briefing covering several concurrent regulatory developments.
- 15 Aug 2026
Bowel Screening Finds 100 Cancers Weekly as 50s Lag
New NHS England figures reveal that people in their 50s are among the least likely age groups to complete bowel cancer screening, despite the programme identifying approximately 100 cancers every week.
- 15 Aug 2026
Europe Fast-Tracks RevMed Cancer Drug Review
European regulators have agreed to expedite their assessment of a cancer drug from Revolution Medicines, according to a July 2026 STAT News report covering several concurrent regulatory developments.
- 15 Aug 2026
European Regulators to Fast-Track RevMed Drug Review
European regulators have moved to expedite their assessment of a Revolution Medicines drug, according to a July 8, 2026 STAT News report covering several regulatory and clinical developments.
- 14 Aug 2026
Bowel Screening Finds 100 Cancers a Week in People in Their 50s
New NHS England figures reveal that bowel cancer screening is detecting roughly 100 cancers per week among people in their 50s, yet participation in this age group continues to trail behind older cohorts.
- 14 Aug 2026
EU Fast-Tracks RevMed Drug, FDA Clears Vera Therapy
European regulators have agreed to accelerate their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several concurrent regulatory developments.
- 14 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
Annual NHS bowel screening figures for 2024–25 reveal around 100 cancers are being detected each week through the programme, even as participation rates among those in their 50s lag behind older eligible adults.
- 14 Aug 2026
EU Fast-Tracks RevMed Drug, FDA Clears Vera Therapy
European regulators have agreed to accelerate their review of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several concurrent regulatory developments.
- 13 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
New NHS England data shows the bowel cancer screening programme is detecting roughly 100 cancers every week, yet participation among people in their 50s remains notably low.
- 13 Aug 2026
EU Expedites RevMed Drug Review in Biotech Roundup
European regulators have moved to fast-track their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several notable regulatory developments.
- 13 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
New NHS England data covering April 2024 to March 2025 shows the bowel cancer screening programme is detecting roughly 100 cancers each week, yet participation among people in their 50s remains notably low.
- 13 Aug 2026
Three Biotech Regulatory Moves Shaping Drug Pipelines
A cluster of regulatory developments is reshaping near-term prospects for three biotechnology companies, spanning oncology, autoimmune disease, and metabolic medicine.
- 12 Aug 2026
EU Expedites RevMed Review; FDA Clears Vera Therapy
European regulators have moved to expedite their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report that also covers an FDA clearance and fresh concerns over an oral GLP-1 program.
- 12 Aug 2026
Bowel Screening Uptake Lags Among People in Their 50s
Annual NHS England figures for 2024–25 reveal that participation in bowel cancer screening is notably lower among people in their 50s compared with other age groups, even as the programme identifies roughly 100 cancers each week.
- 12 Aug 2026
Biotech Regulatory Roundup: Three Drugs in Focus
Three notable regulatory and clinical developments emerged in early July 2026, spanning a European accelerated review, an FDA clearance, and fresh scrutiny of an oral weight-loss candidate.
- 11 Aug 2026
Bowel Screening Gaps Found in People in Their 50s
New NHS England figures reveal that people in their 50s are among the least likely age groups to complete bowel cancer screening, despite the programme detecting roughly 100 cancers every week.
- 11 Aug 2026
Three Biotech Regulatory Shifts Reshape Drug Pipelines
A cluster of regulatory developments is reshaping several drug pipelines, from an accelerated European review of a Revolution Medicines oncology candidate to fresh questions surrounding an oral GLP-1 compound.
- 11 Aug 2026
Bowel Screening in the 50s: 100 Cancers Found Weekly
New NHS England figures covering April 2024 to March 2025 reveal that people in their 50s are among the least likely age groups to return bowel cancer screening kits, despite the programme detecting roughly 100 cancers a week within that demographic.
- 11 Aug 2026
EU Expedites RevMed Drug Review in Biotech Update
European regulators have agreed to expedite their review of a Revolution Medicines cancer drug, according to a July 2026 STAT News report covering several notable regulatory developments.
- 10 Aug 2026
Bowel Screening Finds 100 Cancers a Week as 50s Lag
New NHS England figures covering April 2024 to March 2025 show the bowel cancer screening programme is identifying around 100 cancers per week, yet uptake among those in their 50s trails other age groups.
- 10 Aug 2026
EU Expedites RevMed Drug Review in Biotech Update
European regulators have moved to expedite their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several concurrent regulatory developments.
- 10 Aug 2026
NHS Bowel Screening Finds 100 Cancers a Week
New NHS England figures covering April 2024 to March 2025 show the bowel cancer screening programme is detecting roughly 100 cancers each week, even as participation among people in their 50s remains below average.
- 10 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have moved to expedite their assessment of a Revolution Medicines oncology drug, one of several regulatory developments reported by STAT News on July 8, 2026.
- 9 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures reveal the bowel cancer screening programme is identifying roughly 100 cancers every week, even as participation among people in their 50s remains notably lower than other age groups.
- 9 Aug 2026
Bowel Screening Finds 100 Cancers Weekly as 50s Lag
New NHS England figures reveal that bowel cancer screening is identifying around 100 cases every week, though participation among people in their 50s remains notably lower than other age groups.
- 9 Aug 2026
European Regulators Fast-Track Revolution Medicines Drug Review
European regulators have moved to expedite their assessment of a Revolution Medicines cancer drug, according to a July 2026 STAT News report covering several notable regulatory and clinical developments.
- 8 Aug 2026
Bowel Screening Uptake Lags in 50s Despite 100 Weekly Cancer Finds
New NHS England figures reveal that participation in bowel cancer screening remains notably low among people in their 50s, despite the programme identifying approximately 100 cancers every week within that cohort.
- 8 Aug 2026
Three Biotech Regulatory Shifts Reshaping Drug Pipelines
A cluster of regulatory decisions is drawing attention across oncology, autoimmune disease, and metabolic medicine, with outcomes that could influence how several drug candidates advance globally.
- 8 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly in Over-50s
New NHS England figures covering April 2024 to March 2025 show that bowel cancer screening is detecting approximately 100 cancers per week among people in their 50s, even as participation rates in this age group lag behind others.
- 8 Aug 2026
Three Biotech Regulatory Developments in Brief
A cluster of regulatory and clinical updates has emerged across the biotech sector, spanning a European review acceleration, an FDA clearance, and fresh concerns over an oral GLP-1 candidate.
- 7 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England data covering April 2024 to March 2025 shows the bowel cancer screening programme is detecting approximately 100 cancers every week, even as participation among people in their 50s remains notably low.
- 7 Aug 2026
European Regulators to Expedite RevMed Drug Review
European regulators have moved to expedite their assessment of a Revolution Medicines drug, according to a STAT News report published July 8, 2026, alongside several other notable regulatory developments.
- 7 Aug 2026
Bowel Cancer Screening Finds 100 Cases a Week in 50s
New NHS England figures show that participation in bowel cancer screening among people in their 50s lags behind other age groups, even as the programme identifies roughly 100 cancers per week in this demographic.
- 7 Aug 2026
Three Biotech Regulatory Shifts Reshaping Drug Pipelines
A cluster of regulatory developments across oncology, autoimmune disease, and metabolic medicine signals shifting fortunes for three biotech companies, according to a STAT News briefing.
- 6 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures covering April 2024 to March 2025 show the bowel cancer screening programme is detecting around 100 cancers every week, even as participation among people in their 50s remains below expectations.
- 6 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have agreed to accelerate their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several notable regulatory developments.
- 6 Aug 2026
Bowel Cancer Screening Finds 100 Cases Weekly in People in Their 50s
New NHS England figures show bowel cancer screening is detecting roughly 100 cancers a week among people in their 50s, yet participation in this age group trails behind older cohorts.
- 6 Aug 2026
EU Fast-Tracks RevMed Drug; FDA Clears Vera Therapy
European regulators have agreed to expedite their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several notable regulatory developments.
- 5 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly as 50s Lag
New NHS England figures covering April 2024 to March 2025 show that people in their 50s are less likely than other age groups to complete bowel cancer screening, with just over half of 54-year-olds participating.
- 5 Aug 2026
RevMed Drug, Vera Therapy, Kailera GLP-1 Pill in Focus
A cluster of regulatory and clinical developments is drawing attention across the biotech sector, with European reviewers moving faster on one cancer drug while questions emerge around an oral GLP-1 candidate.
- 5 Aug 2026
EU Expedites RevMed Drug Review in Biotech Roundup
European regulators have moved to expedite their assessment of a Revolution Medicines oncology drug, according to a July 2026 STAT News report covering several notable regulatory developments.
- 4 Aug 2026
Bowel Screening Finds 100 Cancers a Week in People in Their 50s
New NHS England figures reveal that people in their 50s are less likely than other age groups to return bowel cancer screening kits, even as the programme detects roughly 100 cancers per week among this demographic.
- 4 Aug 2026
Europe Fast-Tracks RevMed Drug, FDA Clears Vera Therapy
European regulators have agreed to accelerate their assessment of a Revolutionary Medicines oncology drug, while the FDA has cleared a Vera autoimmune therapy and questions have surfaced around oral GLP-1 data from Kailera.
- 4 Aug 2026
Bowel Screening Finds 100 Cancers a Week as 50s Lag
New NHS England figures show that people in their 50s are among the least likely age groups to complete bowel cancer screening, despite the programme identifying roughly 100 cancers every week.
- 4 Aug 2026
EU Fast-Tracks RevMed Drug, FDA Clears Vera Therapy
European regulators have agreed to accelerate their assessment of a Revolution Medicines oncology drug, while separate decisions from the FDA and emerging clinical data added further movement to the biotech landscape this week.
- 3 Aug 2026
NHS Bowel Screening Finds 100 Cancers Weekly
New NHS England figures covering April 2024 to March 2025 show the bowel cancer screening programme is identifying roughly 100 cancers every week, even as participation rates among people in their 50s lag behind older cohorts.
- 3 Aug 2026
European Regulators Fast-Track Revolution Medicines Drug
European drug regulators have moved to expedite their assessment of a Revolution Medicines oncology candidate, according to a July 2026 STAT News report covering several notable regulatory developments.